Hydroxycarbamide Medac (Hydroxycarbamide)

Hydroxycarbamide blocks the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides into deoxyribonucleotides. By limiting the supply of DNA building blocks, the drug slows DNA synthesis and curtails the proliferation of rapidly dividing cells, such as malignant or sickled red blood cells.

The dose of Hydroxycarbamide Medac is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and response to therapy. Dosage adjustments are made according to laboratory monitoring and clinical judgment.

Hydroxycarbamide is classified with an unknown pregnancy category, and limited data exist on its safety during lactation. It should only be used when the potential benefit justifies the possible risk to the fetus or infant, and treatment decisions should involve a specialist in maternal‑fetal medicine.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Hydroxycarbamide belongs to the antimetabolite class and is distinct from agents such as methotrexate or cytarabine, which target different enzymes. Compared with methotrexate, hydroxycarbamide has a more specific effect on ribonucleotide reductase and is often preferred for chronic myelogenous leukemia and sickle cell disease due to its oral administration and established efficacy profile.

Hydroxycarbamide Medac should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Hydroxycarbamide Medac is taken orally, usually as a tablet. It can be swallowed with water, with or without food, unless the prescribing physician advises otherwise. Patients should follow the exact dosing schedule provided by their healthcare professional.

The most serious adverse effects include bone‑marrow suppression leading to neutropenia or thrombocytopenia, severe infections, hepatic toxicity, renal impairment, and rare hypersensitivity reactions. Regular laboratory monitoring is essential to detect these complications early and adjust therapy as needed.

Hydroxycarbamide Medac is contraindicated in patients with known hypersensitivity to hydroxycarbamide or any of its excipients, those with severe bone‑marrow failure, and individuals with active, uncontrolled infections. Caution is also advised for pregnant or breastfeeding women, and the drug should be avoided unless the therapeutic benefit outweighs potential risks.